These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

691 related articles for article (PubMed ID: 28138429)

  • 21. High Correlation of Static First-Minute-Frame (FMF) PET Imaging after
    Seiffert AP; Gómez-Grande A; Villarejo-Galende A; González-Sánchez M; Bueno H; Gómez EJ; Sánchez-González P
    Sensors (Basel); 2021 Jul; 21(15):. PubMed ID: 34372416
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Concordance in detecting amyloid positivity between
    Cho SH; Choe YS; Kim YJ; Lee B; Kim HJ; Jang H; Kim JP; Jung YH; Kim SJ; Kim BC; Farrar G; Na DL; Moon SH; Seo SW
    Sci Rep; 2020 Nov; 10(1):19576. PubMed ID: 33177593
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Dual-biomarker imaging of regional cerebral amyloid load and neuronal activity in dementia with PET and 11C-labeled Pittsburgh compound B.
    Meyer PT; Hellwig S; Amtage F; Rottenburger C; Sahm U; Reuland P; Weber WA; Hüll M
    J Nucl Med; 2011 Mar; 52(3):393-400. PubMed ID: 21321269
    [TBL] [Abstract][Full Text] [Related]  

  • 24. PET quantification of 18F-florbetaben binding to β-amyloid deposits in human brains.
    Becker GA; Ichise M; Barthel H; Luthardt J; Patt M; Seese A; Schultze-Mosgau M; Rohde B; Gertz HJ; Reininger C; Sabri O
    J Nucl Med; 2013 May; 54(5):723-31. PubMed ID: 23471310
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cerebral amyloid-β PET with florbetaben (18F) in patients with Alzheimer's disease and healthy controls: a multicentre phase 2 diagnostic study.
    Barthel H; Gertz HJ; Dresel S; Peters O; Bartenstein P; Buerger K; Hiemeyer F; Wittemer-Rump SM; Seibyl J; Reininger C; Sabri O;
    Lancet Neurol; 2011 May; 10(5):424-35. PubMed ID: 21481640
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Feasibility evaluation of middle-phase
    Wu CH; Lu YH; Lee TH; Tu CY; Fuh JL; Wang YF; Yang BH
    Quant Imaging Med Surg; 2023 Aug; 13(8):4806-4815. PubMed ID: 37581034
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Age dependence of brain β-amyloid deposition in Down syndrome: An [18F]florbetaben PET study.
    Jennings D; Seibyl J; Sabbagh M; Lai F; Hopkins W; Bullich S; Gimenez M; Reininger C; Putz B; Stephens A; Catafau AM; Marek K
    Neurology; 2015 Feb; 84(5):500-7. PubMed ID: 25568295
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Imaging characteristic of dual-phase (18)F-florbetapir (AV-45/Amyvid) PET for the concomitant detection of perfusion deficits and beta-amyloid deposition in Alzheimer's disease and mild cognitive impairment.
    Lin KJ; Hsiao IT; Hsu JL; Huang CC; Huang KL; Hsieh CJ; Wey SP; Yen TC
    Eur J Nucl Med Mol Imaging; 2016 Jul; 43(7):1304-14. PubMed ID: 27003417
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clinical Utility of β-Amyloid PET Imaging in People Living With HIV With Cognitive Symptoms.
    Vera JH; Eftychiou N; Schuerer M; Rullmann M; Barthel H; Sabri O; Gisslen M; Zetterberg H; Blennow K; O'Brien C; Banerjee S; Dizdarevic S
    J Acquir Immune Defic Syndr; 2021 Jun; 87(2):826-833. PubMed ID: 33587503
    [TBL] [Abstract][Full Text] [Related]  

  • 30. 18F-florbetapir PET in patients with frontotemporal dementia and Alzheimer disease.
    Kobylecki C; Langheinrich T; Hinz R; Vardy ER; Brown G; Martino ME; Haense C; Richardson AM; Gerhard A; Anton-Rodriguez JM; Snowden JS; Neary D; Pontecorvo MJ; Herholz K
    J Nucl Med; 2015 Mar; 56(3):386-91. PubMed ID: 25655625
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A modified method of 3D-SSP analysis for amyloid PET imaging using [¹¹C]BF-227.
    Kaneta T; Okamura N; Minoshima S; Furukawa K; Tashiro M; Furumoto S; Iwata R; Fukuda H; Takahashi S; Yanai K; Kudo Y; Arai H
    Ann Nucl Med; 2011 Dec; 25(10):732-9. PubMed ID: 21792587
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Evaluation of 10-minute post-injection 11C-PiB PET and its correlation with 18F-FDG PET in older adults who are cognitively healthy, mildly impaired, or with probable Alzheimer's disease.
    Carneiro CG; Faria DP; Coutinho AM; Ono CR; Duran FLS; da Costa NA; Garcez AT; da Silveira PS; Forlenza OV; Brucki SMD; Nitrini R; Busatto G; Buchpiguel CA
    Braz J Psychiatry; 2022 Aug; 44(5):495-506. PubMed ID: 36420910
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A Cross-Validation of FDG- and Amyloid-PET Biomarkers in Mild Cognitive Impairment for the Risk Prediction to Dementia due to Alzheimer's Disease in a Clinical Setting.
    Iaccarino L; Chiotis K; Alongi P; Almkvist O; Wall A; Cerami C; Bettinardi V; Gianolli L; Nordberg A; Perani D
    J Alzheimers Dis; 2017; 59(2):603-614. PubMed ID: 28671117
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Validation of amyloid PET positivity thresholds in centiloids: a multisite PET study approach.
    Royse SK; Minhas DS; Lopresti BJ; Murphy A; Ward T; Koeppe RA; Bullich S; DeSanti S; Jagust WJ; Landau SM;
    Alzheimers Res Ther; 2021 May; 13(1):99. PubMed ID: 33971965
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Correlation of early-phase 18F-florbetapir (AV-45/Amyvid) PET images to FDG images: preliminary studies.
    Hsiao IT; Huang CC; Hsieh CJ; Hsu WC; Wey SP; Yen TC; Kung MP; Lin KJ
    Eur J Nucl Med Mol Imaging; 2012 Apr; 39(4):613-20. PubMed ID: 22270508
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparison of qualitative and quantitative imaging characteristics of [11C]PiB and [18F]flutemetamol in normal control and Alzheimer's subjects.
    Mountz JM; Laymon CM; Cohen AD; Zhang Z; Price JC; Boudhar S; McDade E; Aizenstein HJ; Klunk WE; Mathis CA
    Neuroimage Clin; 2015; 9():592-8. PubMed ID: 26640770
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Assessment of perfusion deficit with early phases of [
    Völter F; Beyer L; Eckenweber F; Scheifele M; Bui N; Patt M; Barthel H; Katzdobler S; Palleis C; Franzmeier N; Levin J; Perneczky R; Rauchmann BS; Sabri O; Hong J; Cumming P; Rominger A; Shi K; Bartenstein P; Brendel M
    Eur J Nucl Med Mol Imaging; 2023 Apr; 50(5):1384-1394. PubMed ID: 36572740
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Paradoxical Cerebral Perfusion in Parkinson's Disease Patients with Orthostatic Hypotension: A Dual-Phase 18F-Florbetaben Positron Emission Tomography Study.
    Yoo SW; Ha S; Yoon H; Yoo JY; Lee KS; Kim JS
    J Parkinsons Dis; 2021; 11(3):1335-1344. PubMed ID: 34024782
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Validation of Noninvasive Tracer Kinetic Analysis of
    Bullich S; Barthel H; Koglin N; Becker GA; De Santi S; Jovalekic A; Stephens AW; Sabri O
    J Nucl Med; 2018 Jul; 59(7):1104-1110. PubMed ID: 29175981
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Imaging of amyloid beta in Alzheimer's disease with 18F-BAY94-9172, a novel PET tracer: proof of mechanism.
    Rowe CC; Ackerman U; Browne W; Mulligan R; Pike KL; O'Keefe G; Tochon-Danguy H; Chan G; Berlangieri SU; Jones G; Dickinson-Rowe KL; Kung HP; Zhang W; Kung MP; Skovronsky D; Dyrks T; Holl G; Krause S; Friebe M; Lehman L; Lindemann S; Dinkelborg LM; Masters CL; Villemagne VL
    Lancet Neurol; 2008 Feb; 7(2):129-35. PubMed ID: 18191617
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 35.